There's been a rapid shift towards decentralization in clinical trials and it's clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, and direct-to-patient supply are virtual tools that existed before the pandemic. But now there's swift adoption of these methods because they've been proven to help launch and complete trials more effectively.
Yet it's important to note that there's a significant learning curve for sponsors as these new methods graduate from early-phase into larger pivotal trials that must prove efficacy. There are pitfalls to avoid and key elements to keep front and center. Most trials won't be fully virtual, but all trials will be more virtual. In this Endpoints News webinar, we've assembled a panel of clinical experts who are running the trials of tomorrow, today. We'll look at:
Which therapeutic areas are ripe for highly decentralized trials? Which areas will be least resistant to this kind of change?
What's the experience of sponsors deploying decentralized elements at scale in late-stage trials?
What are the challenges in supplying drug products for late-stage decentralized trials?
How should sponsors be thinking about validating remote data?
What are some of the most effective technological solutions to accelerate trial deployment?